Objective:

To analyze the commercial dynamics of GLP-1 obesity drugs in comparison to Lipitor, highlighting potential risks from parallel imports and the implications for market structure.

Key Findings:

• Lipitor's sales in Norway were significantly impacted by parallel imports during its patent period, with pharmacy chains favoring these imports for higher profit margins.
• Pharmacy chains preferred parallel imports for higher profit margins, leading to a 90% market share in the atorvastatin segment.
• Econometric modeling suggests Pfizer's sales could have been over 100% higher without parallel trade, highlighting the critical role of market structure.

Interpretation:

The findings indicate that GLP-1 drugmakers may face similar challenges as Lipitor due to structural market dynamics, the prevalence of parallel imports, and the influence of pharmacy chains.

Limitations:

• The analysis is based on a specific case in Norway and may not fully represent other markets.
• The focus on Lipitor may overlook other factors influencing GLP-1 drug adoption, and the variability of parallel import impacts across different countries.

Conclusion:

The Lipitor case serves as a cautionary tale for GLP-1 drugmakers regarding the risks of parallel imports and the importance of understanding market structure in Europe.